FiercePharma  May 20  Comment 
FDA staffers air concerns over Novo's Victoza-Tresiba combo chelfand Fri, 05/20/2016 - 12:12
FierceBiotech  May 20  Comment 
In a showdown with Sanofi, FDA questions Novo’s PhIII data for IDegLira john_carroll Fri, 05/20/2016 - 10:43
Motley Fool  May 5  Comment 
The diabetes-drug specialist releases earnings and shares positive clinical trial data for future growth.
SeekingAlpha  Apr 29  Comment 
The Times of India  Apr 29  Comment 
Copenhagen, April 29, 2016 (AFP) -The world's largest maker of diabetes treatments, Novo Nordisk, said on Friday that the US launch of ultra-long acting insulin Tresiba had been "encouraging" as it reported a drop in first quarter profit. Net...

You may also be interested in articles related to Novo Nordisk A/S (NVO):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki